INTRODUCTION
============

Testosterone replacement therapy has become widely accepted for treating age-related and other forms of hypogonadism in men, and is associated with improved mood, increased sexual desire and performance, increased muscle mass and bone mineral density, and improved quality of life.^[@R1]--[@R6]^ Prostate cancer is the most commonly diagnosed male cancer, typically in the sixth and seventh decades of life, and the lifetime risk is approximately 16%.^[@R7]^ Screening for prostate cancer includes measurement of prostate-specific antigen (PSA) level and digital rectal examination.^[@R8]^ PSA levels are increased in patients with prostate cancer, and a PSA level ≥4.0 ng/mL is generally considered elevated and a further evaluation, including a biopsy, is typically performed.^[@R8]^ PSA is prostate specific, but not prostate cancer specific, and levels can be altered by medications, benign prostatic hypertrophy (BPH), prostatitis, and urologic manipulations.^[@R8]^

Reducing androgen levels to the castrate range has been clearly shown to reduce prostate cancer growth.^[@R9]^ Conversely, based on early reports, the administration of testosterone was believed to promote prostate cancer growth, and was considered contraindicated in men at risk for prostate cancer.^[@R10],[@R11]^ With the identification of the adverse consequences of low testosterone levels in men with aging, and the benefits of testosterone replacement, the association of prostate cancer and testosterone has been reexamined and current suggests that testosterone replacement is safe with respect to the development of prostate cancer.^[@R1],[@R12]--[@R15]^

As PSA is a primary screening tool for prostate cancer, and testosterone replacement therapy is being widely used for the treatment of age-related male hypogonadism, the purpose of this systematic review and meta-analysis was to determine the effect of testosterone replacement therapy on PSA levels in men being treated for hypogonadism.

MATERIALS AND METHODS
=====================

Literature Search Strategy
--------------------------

This systematic review and meta-analysis was conducted in accordance with PRISMA guidelines.^[@R16]^*Medline*, *Cochrane Library*, *EMBASE*, and *Google Scholar* databases were searched until February 28, 2014, using combinations of the following search terms: testosterone, androgen, prostate cancer, prostatic neoplasms, prostate-specific antigen, PSA, hypogonadism, and gonadal disorders. Reference lists of relevant studies were hand searched. Ethical approval of this study was waived, as systematic review and meta-analyses do not involve patients.

Selection Criteria and Data Extraction
--------------------------------------

Inclusion criteria were as follows: randomized controlled trial or prospective nonrandomized study; intervention group received testosterone replacement therapy or androgen replacement therapy; control group did not receive testosterone and may have received placebo or conventional treatment; 18 or more years of age; male gender; no history of prostate cancer. Retrospective studies, single-arm studies, those with no numerical data for the outcomes of interest, and letters, comments, case studies, and editorials were excluded. Studies were identified by the search strategy by 2 independent reviewers, and a third reviewer was consulted when disagreement arose.

Data extracted from studies that met the inclusion criteria were the name of the first author, year of publication, study design, demographic data of individuals, dosage and administration of testosterone, and outcomes. Data extraction was performed by 2 independent reviewers, and a third reviewer was consulted for any uncertainties.

Quality Assessment
------------------

The methodological quality of each study was assessed using the risk-of-bias assessment tool outlined in the Cochrane Handbook for Systematic Reviews of Interventions (version 5.1.0)^[@R17]^ by 2 reviewers, and a third reviewer was consulted for any uncertainties.

Outcome Measures and Data Analysis
----------------------------------

The primary outcome measure was the change of PSA level between before and after treatment (PSA~after~ - PSA~before~). The secondary outcomes were the number of patients with an elevated PSA level after treatment, and the number of patients who developed prostate cancer. Data between groups were compared overall, and by route of administration. For the difference of PSA levels between before and after treatment, the difference in means with 95% confidence interval (CI) between testosterone and control treatments was calculated. A difference in means \>0 indicates testosterone is favored, which means that testosterone was associated with a greater change in PSA level than control treatment, whereas a difference in means \<0 indicates testosterone was associated with a smaller change in PSA level than control treatment. Odds ratios (OR) with 95% CIs were calculated and compared between testosterone and control treatments. An OR \>1 indicates testosterone is associated with a higher percentage of patients with an elevated level than control treatment, whereas an OR \<1 indicates testosterone is associated with a lower percentage than control treatment.

A χ^2^--based test of homogeneity was performed using Cochran Q statistic and I^2^. I^2^ indicates the percentage of the total variability in effect estimates among trials because of heterogeneity rather than chance. Random-effects models of analysis were used if heterogeneity was detected (*P* \< 0.10, I^2^ \> 50%). Otherwise, fixed-effects models were used. Pooled difference in means and pooled ORs with corresponding 95% CIs were calculated, and a 2-sided *P* \< 0.05 was considered to indicate statistical significance. Sensitivity analysis was carried out for the outcomes using the leave-one-out approach. Publication bias was assessed by constructing a funnel plot and by Egger test. The absence of publication bias is indicated by the data points forming a symmetric funnel-shaped distribution, and a one-tailed significance level \>0.05 in Egger test. All analyses were performed using Comprehensive Meta-Analysis statistical software, version 2.0 (Biostat, Englewood, NJ).

RESULTS
=======

Literature Search
-----------------

A flow diagram of study selection is shown in Figure [1](#F1){ref-type="fig"}. After initially identifying 511 articles, 430 were excluded and the full texts of 81 were reviewed. Subsequently, 66 were excluded and 15 studies were included in the systematic review and meta-analysis (Table [1](#T1){ref-type="table"}).

![Flow diagram of study selection.](medi-94-e410-g001){#F1}

###### 

Characteristics of the Studies Included in the Meta-Analysis
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Study Characteristics and Quality Assessment
--------------------------------------------

Characteristics of the 15 studies included in the meta-analysis are summarized in Table [1](#T1){ref-type="table"}, and outcomes are summarized in Table [2](#T2){ref-type="table"}. The number of participants that received testosterone treatment ranged from 5 to 237 (total = 739), and the number of participants in the control groups ranged from 5 to 112 (total = 385). In 6 studies, testosterone was administered transdermally, in 7 intramuscularly (IM), and in 2 orally, and the duration of treatment ranged from 3 to 12 months.

###### 

Clinical Outcomes (PSA Levels and Elevated PSA Concentrations) of Included Studies
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The results of the quality assessment of the included studies are shown in Supplemental Figure 1 (<http://links.lww.com/MD/A156>). Possible performance bias from inappropriate blinding of participants and personnel might be present in 6 studies, and 1 study did not clearly state the blinding process; thus, 53.3% (8/15) of studies had low performance bias (blinding of participants and personnel), and 40.0% (6/15) of studies had high performance bias.

Outcome Measures
----------------

### Change of PSA Level

Nine of the 15 studies provided complete data regarding PSA levels before and after treatment (Figure [2](#F2){ref-type="fig"}). In 4 studies, testosterone was administered transdermally, in 4 IM, and in 1 orally. There was no evidence of heterogeneity among the 9 studies (Q statistic = 6.12, I^2^ = 0%, *P* = 0.634); thus, a fixed-effects model was used. Overall, patients treated with testosterone tended to have higher PSA levels after treatment, and thus a greater change than those that received control treatments (difference in means of PSA levels = 0.154, 95% CI 0.069--0.238, *P* \< 0.001). The difference in means of PSA levels were significant higher for patients that received testosterone via the IM route than controls (difference in means of PSA levels = 0.271, 95% CI 0.117--0.425, *P* = 0 .001). The difference in means of PSA levels were similar between patients who received testosterone transdermally and controls (difference in means of PSA levels = 0.085, 95% CI: −0.021 to 0.190, *P* = 0.116).
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### Elevated PSA Level After Treatment

Seven of the 15 studies provided complete data regarding the number of patients with elevated PSA after treatment; however, 2 studies reported zero patients in the control groups,^[@R21],[@R22]^ and thus the 2 studies were excluded from the analysis because zero cannot be used to calculate an OR (Figure [3](#F3){ref-type="fig"}). In 2 studies, testosterone was administered transdermally, and in 2 IM. In only 1 study was testosterone given orally,^[@R24]^ and that study included 3 intervention groups and 1 control group. Because the study found no difference in relevant PSA elevations between the 3 treatment groups, we pooled the data of the 3 intervention groups and compared the pooled data with the control group and obtained an OR. There was no evidence of heterogeneity among the 5 studies (Q statistic = 4.16, I^2^ = 3.72%, *P* = 0.385); thus, a fixed-effects model was used. The rates of elevated PSA levels after treatment were similar between patients that received testosterone and controls (OR = 1.02, 95% CI 0.48--2.20, *P* = 0.953). The results were similar when the analysis was performed for testosterone given transdermally and IM.
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### Development of Prostate Cancer

Only 3 studies provided data with respect to the development of prostate cancer (Table [2](#T2){ref-type="table"}). Shigehara et al^[@R21]^ reported no cases of prostate cancer in the testosterone or control groups with a treatment duration of 12 months. Marks et al^[@R25]^ reported a prostate cancer rate of 9.5% in the testosterone group as compared with a 21.1% rate in the control group with a treatment duration of 12 months.

Sensitivity Analysis
--------------------

Sensitivity analyses using the leave-one-out approach indicated the direction and magnitude of the combined estimates did not change markedly with the exclusion of individual studies, indicating that the meta-analysis had good reliability (Supplemental Figure 2, <http://links.lww.com/MD/A157>, <http://links.lww.com/MD/A158>).

Publication Bias
----------------

Funnel plot symmetry and Egger test indicated there was no publication bias for either PSA level change between before and after treatment or elevated PSA level after treatment (Supplemental Figure 3, <http://links.lww.com/MD/A159>, <http://links.lww.com/MD/A160>).

DISCUSSION
==========

The results of this meta-analysis showed that testosterone replacement was not associated with an increase in PSA level, although a slight increase was seen when testosterone was given IM. Although only 3 of the 15 studies reported the incidence of prostate cancer, there was no difference between the treatment and control groups in the 3 studies.

Early studies suggested that the administration of testosterone could promote prostate cancer growth,^[@R10],[@R11]^ and later studies showed that reducing androgen levels to the castrate range reduced prostate cancer growth.^[@R9]^ These data led to the supposition that raising serum testosterone levels with replacement therapy could cause an occult prostate tumor to grow into an aggressive lesion.^[@R13]^ Current data, however, indicate that variations of testosterone levels within the physiological range have little, if any, impact on prostate cancer growth, a low testosterone level may be associated with a high-risk for developing prostate cancer, and that normal testosterone levels play a protective role against prostate cancer.^[@R13],[@R14],[@R31]--[@R33]^

Of the studies included in this meta-analysis, the earliest was performed in 1997 by Sih et al,^[@R30]^ who studied hypogonadal men with a mean age of 68 years and reported that testosterone supplementation (200 mg testosterone cypionate biweekly for 12 months) improved strength, increased hemoglobin levels, and lowered leptin levels. Andrade et al^[@R2]^ also treated hypogonadal men with IM testosterone for 6 months and reported an improvement in body composition. Chiang et al^[@R23]^ and Park et al^[@R4]^ both reported that testosterone replacement improved quality of life and sexual function in men with testosterone deficiency. In one of the larger studies included in the current analysis, Legros et al^[@R24]^ examined the effect of oral testosterone undecanoate in men with symptomatic hypogonadism in a multicenter, randomized, double-blind, placebo-controlled trial and found that testosterone replacement did not improve the total Aging Males' Symptom score after 6 months of treatment, except in the sexual symptom subdomain were a modest improvement seen with a dose of 160 mg/day. In other included studies, Bauman et al^[@R19]^ reported that transdermal testosterone improved lean tissue mass in men with spinal cord injuries, and Merza et al^[@R26]^ found that transdermal testosterone increased lean body mass and decreased bone absorption in men with borderline hypogonadism. Interestingly, 2 of the included studies examined the effect of testosterone replacement in men with type 2 diabetes mellitus and whereas one^[@R22]^ found that IM testosterone did not have an effect on insulin resistance or dyslipidemia, the other^[@R20]^ showed that transdermal replacement had a beneficial effect on insulin resistance and lipid levels. Importantly, Marks et al^[@R25]^ showed that 6 months of IM testosterone enanthate normalized serum testosterone levels and had little effect on prostate tissue androgen levels or function.

With respect to PSA levels, although not included in the meta-analysis, El-Sakka et al^[@R34]^ showed no significant change in PSA level after 1 year of testosterone replacement in hypogonadal men with erectile dysfunction, with other studies reporting similar findings.^[@R35],[@R36]^ Coward et al^[@R37]^ showed that PSA levels remain stable after administration of testosterone for ≥5 years, and that the incidence of prostate cancer in men receiving replacement therapy was no greater than that of the general population. The contradiction that androgen deprivation can markedly reduce the growth of prostate cancer while administration of testosterone replacement does not affect prostate cancer incidence or growth has been addressed by the saturation model.^[@R14]^ The model is based on the observation that the prostate is very sensitive to changes in androgens at low concentrations, but exhibits little or no sensitivity to changes at higher androgen concentrations, that is, there is a plateau at which further increases in androgen concentrations elicit no additional response from the prostate.

A primary limitation of this study is the heterogeneity of the studies including the populations examined, testosterone replacement regimes, dosages, and length of therapy, and baseline PSA levels. In addition, data in the studies included were not sufficient to estimate the risk of developing prostate cancer.

CONCLUSION
==========

The results of this study indicate that testosterone replacement therapy does not increase PSA levels in men being treated for hypogonadism, except when it is given IM and even the increase with IM administration is minimal. Data of the included studies were not sufficient to evaluate the risk of prostate cancer with testosterone replacement therapy; however, based on evidence in the literature it does not appear that the risk of prostate cancer is affected by testosterone replacement therapy.

Abbreviations: BPH = benign prostatic hypertrophy, CI = confidence interval, DM = diabetes mellitus, HIV = human immunodeficiency virus, IM = intramuscular, OR = odds ratio, PO = oral/per os, PSA = prostate-specific antigen, RCT = randomized controlled trial.
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